公衆衛生87巻2号

2023年02月発行

特集 シリーズ 公衆衛生と感染症—感染症に対する医薬品開発と医療の最前線

結核に対する医薬品の開発と使用の最前線

著者： 露口一成¹

所属機関： ¹国立病院機構近畿中央呼吸器センター臨床研究センター感染症研究部

ページ範囲：P.130 - P.138

ポイント
◆現在の結核対策における問題は、難治性である多剤耐性結核の治療である。
◆ベダキリン、デラマニドなどの新規薬剤や、リネゾリド、フルオロキノロンなど既存薬の活用により多剤耐性結核の治療成績は向上している。
◆全ての結核症例に対し、感受性を踏まえた適切な多剤併用療法により治癒に導くことが重要である。

参考文献

1）World Healgh Organization: Global tuberculosis report 2021.

2）厚生労働省：2021年 結核登録者情報調査年報集計結果について．　https://www.mhlw.go.jp/content/10900000/000981709.pdf（2022年11月16日閲覧）

3）Daniel TM: Selman Abraham Waksman and the discovery of streptomycin. Int J Tuberc Lung Dis 9: 120-122, 2005

4）Mitchison D, et al: The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16: 724-732, 2012

5）Tsukamura M, et al: Therapeutic effect of a new antibacterial substance ofloxacin（DL8280）on pulmonary tuberculosis. Am Rev Respir Dis 131: 352-356, 1985

6）Yew WW, et al: Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117: 744-751, 2000

7）Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, et al: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392: 821-834, 2018

8）Diacon AH, et al: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405, 2009

9）Gler MT, et al: Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160, 2012

10）Sotgiu G, et al: Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40: 1430-1442, 2012

11）Lan Z, et al: Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 8: 383-394, 2020

12）World Healgh Organization: WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva2020

13）Working Group on New TB Drugs: trach the profress.　https://www.newtbdrugs.org（2022年10月13日閲覧）

14）Nuermberger EL, et al: GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrob Agents Chemother 66: e0013222, 2022

15）Xu J, et al: Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother 65: e02418-20, 2021

16）Rubin EJ: Reviving a Drug for Tuberculosis?. N Engl J Med 376: 2292-2294, 2017

17）Zhu H, et al: Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother 65: e02164-20, 2021

18）Hariguchi N, et al：OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother 64: e02020-19, 2020

19）Talley AK, et al: First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase（GyrB）Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother 65: e0120821, 2021

20）Tenero D, et al: First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. Antimicrob Agents Chemother 63: e00240-19, 2019

21）de Jager VR, et al: Telacebec（Q203）, a New Antituberculosis Agent. N Engl J Med 382: 1280-1281, 2020

22）Tahlan K, et al: SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809, 2012